Tag: ADaM

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)

November 2, 2025

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C) From Pre-IND to IND: A US-First FDA Meeting Strategy with Reviewer-Ready Packages and Predictable Outcomes (Type B/C) Outcome-Oriented Game Plan: What “Good” Looks Like from Pre-IND to IND (US-First with EU/UK Mapping) Decisions before documents: frame the meeting around outcomes The most successful sponsors…

US Regulatory Submissions

Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations

November 2, 2025

digi

Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations Enrollment Funnel Analytics: How to Find the Leaks and Lift Randomizations with a System You Can Defend Why enrollment funnels decide study success—and how analytics turns “maybe” into predictable randomizations From activity to outcomes: measuring the right moments in the funnel Every clinical program lives or dies…

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)

November 2, 2025

digi

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C) From Pre-IND to IND: A US-First FDA Meeting Strategy with Reviewer-Ready Packages and Avoidable Pitfalls (Type B/C) Outcome-Oriented Game Plan: What “Good” Looks Like from Pre-IND to IND (US-First with EU/UK Mapping) Decisions before documents: frame the meeting around outcomes The most successful sponsors…

US Regulatory Submissions